This article queries the pharmaceutical industry's concept of “ready-torecruit” populations by examining its recruitment strategies for clinical trials and the types of human subjects who participate in these drug studies. The argument is that the pharmaceutical industry has profited from a system composed of what can more aptly be characterized as ready-to-consent populations, meaning populations who do not have better alternatives than participation in clinical trials. Furthermore, through qualitative research, this article aims to highlight some of the limitations of current U.S. federal regulation and to show how these limits signal problems that are not normally discussed in the medical ethics literature about research on human subjects. It does this by examining the impotence of informed consent—both as a concept and as a practice—in light of recruitment strategies and the structural reasons motivating individuals to participate in clinical trials.
Anderson, D.L. (2004). A guide to patient recruitment and retention. Boston: Thomson CenterWatch.
2.
Appelbaum, P.S., & Lidz, C.W. (in press). The therapeutic misconception. In E. J. Emanuel, R. A. Crouch, C. Grady, R. Lie, F. Miller, & D. Wendler (Eds.), The Oxford textbook of clinical research ethics . New York: Oxford University Press .
3.
Brown, D.R., & Topcu, M. (2003). Willingness to participate in clinical treatment research among older African Americans and Whites. The Gerontologist , 43, 62—72.
4.
Caplan, A. (1998). Due consideration: Controversy in the age of medical miracles. New York: John Wiley.
5.
CenterWatch. (2005). An industry in evolution (5th ed). Boston: Thomson CenterWatch.
6.
Chun, M., & McEneaney, E.H. (2006, August). Personhood and the balance of risk and benefit: Analyzing the participation of foster children in clinical trials. Paper presented at the meeting of the American Sociological Association in Montreal, Canada.
7.
Corbie-Smith, G., Thomas, S.B., & St. George, D.M.M. (2002). Distrust, race, and reasearch . Archives of Internal Medicine, 162, 2458—2463.
8.
Corrigan, O.P. (2003). Empty ethics: The problem with informed consent . Sociology of Health and Illness, 25, 768—792.
9.
Epstein, S. (2004). Bodily differences and collective identities: The politics of gender and race in biomedical research in the United States . Body & Society, 10, 183—203.
10.
Epstein, S. (2007). Inclusion: The politics of difference in medical research. Chicago: University of Chicago Press.
11.
Epstein, S. (in press). The rise of “recruitmentology”: Clinical research, racial knowledge, and the politics of inclusion and difference. Social Studies of Science.
12.
Faden, R.R., & Beauchamp, T.L. (1986). A history and theory of informed consent. New York: Oxford University Press.
13.
Fisher, J.A. (2005). Pharmaceutical paternalism and the privatization of clinical trials. Unpublished doctoral dissertation, Rensselaer Polytechnic Institute, Troy, NY.
14.
Fisher, J.A. (2006a). Co-ordinating “ethical” clinical trials: The role of research coordinators in the contract research industry . Sociology of Health and Illness, 28(6), 678-694.
15.
Fisher, J.A. (2006b). Procedural misconceptions and informed consent: Insights from empirical research on the clinical trials industry. Kennedy Institute of Ethics Journal, 16(3), 251—268.
16.
Fisher, J.A. (in press). Medical Research for Hire: The Political Economy of Pharmaceutical Clinical Trials. New Brunswick, NJ: Rutgers University Press.
17.
Fuqua, J.V. (2002). “Ask your doctor about . . .”: Direct-to-consumer prescription drug advertising and the HIV/AIDS medical marketplace. Cultural Studies, 16(5), 650—672.
18.
Gamble, V.N. (2000). Under the shadow of Tuskegee: African Americans and health care. In S. M. Reverby (Ed.), Tuskegee's truths: Rethinking the Tuskegee syphilis study (pp. 431—442). Chapel Hill: University of North Carolina Press.
19.
Hall, B. (1992). From margins to center? The development and purpose of participatory research. American Sociologist, 22, 15—28.
20.
Halpern, S.A. (2004). Lesser harms: The morality of risk in medical research. Chicago: University of Chicago Press.
21.
Harkness, J.H. (1996). Research behind bars: A history of nontherapeutic research on American prisoners. Unpublished doctoral dissertation, University of Wisconsin, Madison.
22.
Healy, D. (2006). The new medical Oikumene. In A. Petryna, A. Lakoff, & A. Kleinman (Eds.), Global pharmaceuticals: Ethics, markets, practices (pp. 61—84). Durham, NC: Duke University Press.
23.
Hornblum, A.M. (1998). Acres of skin: Human experiments at Holmesburg Prison. New York: Routledge.
24.
Institute of Medicine. (2002). Responsible research: A systems approach to protecting research participants . Washington, DC: National Academies Press.
25.
Jones, J.H. (1981). Bad blood: The Tuskegee syphilis experiment. New York: Free Press.
26.
King, P.A. (2000). The dangers of difference. In S. M. Reverby (Ed.), Tuskegee's truths: Rethinking the Tuskegee syphilis study (pp. 424—430). Chapel Hill: University of North Carolina Press.
27.
Lynch, G.F., Gorelick, P.B., Raman, R., & Leurgans, S. (2001). A pilot survey of African-American physician perceptions about clinical trials. Journal of the National Medical Association , 93(12), 8S-13S.
28.
Mirowski, P., & Van Horn, R. (2005). The contract research organization and the commercialization of scientific research. Social Studies of Science, 35(4), 503—548.
29.
Petryna, A. (2006). Globalizing human subjects research. In A. Petryna, A. Lakoff, & A. Kleinman (Eds.), Global Pharmaceuticals: Ethics, markets, practices (pp. 33—60). Durham, NC: Duke University Press.
30.
Rainville, B. (2002). Strategic outsourcing with contract research organizations: Targeting corporate goals. Drug Information Journal, 36(1), 77—81.
31.
Reason, P., & Bradbury, H. (Eds.). (2006). Handbook of action research . Thousand Oaks, CA: Sage.
32.
Reverby, S. M. (Ed.). (2000). Tuskegee's truths: Rethinking the Tuskegee syphilis study. Chapel Hill: University of North Carolina Press.
33.
Ronald, L. (2006). Empowered to consume: Direct-to-consumer advertising and pharmaceutical governance. Unpublished doctoral dissertation, Rensselaer Polytechnic Institute, Troy, NY.
34.
Rosenthal, E. (2006, April 8). British rethinking rules after ill-fated drug trial. New York Times. Retrieved from http://www.nytimes.com/2006/04/08/world/europe/08britain.html?ex=1180411200&en=7f53f64a1a24dca7&ei=5070
35.
Sherwin, S. (1996). Feminism and bioethics. In S. M. Wolf (Ed.), Feminism & bioethics: Beyond reproduction (pp. 47—66). New York: Oxford University Press.
36.
Sherwin, S. (Ed.). (1998). The politics of women's health: Exploring agency and autonomy. Philadelphia: Temple University Press.
37.
Veatch, R.M. (1987). The patient as partner: A theory of human-experimentation ethics. Bloomington: Indiana University Press.
38.
Wolpe, P.R. (1998). The triumph of autonomy in American bioethics: A sociological perspective. In R. DeVries & J. Subedi (Eds.), Bioethics and society: Constructing the ethical enterprise (pp. 38—59). Upper Saddle River, NJ: Prentice Hall.
